Peptable

Comparison

Dulaglutide vs TB-500

Function

While Dulaglutide is a once-weekly GLP-1RA for type 2 diabetes that lowers HbA1c and body weight by enhancing glucose-dependent insulin secretion and reducing appetite6668, TB-500 is studied for enhancing musculoskeletal and cardiac repair, wound healing, and promoting cell migration and differentiation via actin cytoskeleton remodeling21255.

Mechanism

While Dulaglutide works as a recombinant fusion protein consisting of two disulfide-linked GLP-1(7–37) analogs each covalently fused via a linker to an IgG4 Fc fragment, yielding a large, long-acting GLP-1 receptor agonist protected from DPP-4 degradation66, TB-500 is a synthetic peptide comprising the LKKTETQ actin-binding motif of thymosin beta-4 that binds G-actin, sequesters actin monomers, and promotes cell migration, angiogenesis, and tissue repair1255.

Receptor

Dulaglutide

GLP-1 receptor (GLP1R) 6680

TB-500

Binds monomeric actin (G-actin) rather than a classical cell-surface receptor, modulating actin polymerization at barbed and pointed ends55

Organism or Origin

Dulaglutide

Engineered human GLP-1 analog–IgG4 Fc fusion protein produced in mammalian cell culture66

TB-500

Synthetic derivative of human thymosin beta-4, whose full-length 43-amino-acid protein is abundant in mammalian tissues21279

Gene

Dulaglutide

GCG

TB-500

TMSB4X

Summary

Dulaglutide and TB-500 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Dulaglutide is more often discussed in the realm of Metabolic and endocrine, whereas TB-500 is more often associated with the realm of Musculoskeletal health and Cardiovascular health. Their biological logic is quite different: Dulaglutide is a receptor agonist, whereas TB-500 is a signaling modulator and a growth factor mimetic. Dulaglutide has a more engineered peptide origin, while TB-500 is closer to synthetic analog background and their development context also differs, with Dulaglutide approved while TB-500 is in Preclinical development. Dulaglutide takes the form of a peptide conjugate, whereas TB-500 is closer to a linear peptide, while their sequence patterns also diverge, with Dulaglutide showing alpha-helical domain features and TB-500 showing protein-mimetic sequence features.

Sources

66Dulaglutide | 923950-08-7 - ChemicalBook, https://amp.chemicalbook.com/ChemicalProductProperty_EN_CB12738186.htm?N=United+Kingdom
68Glucagon-like peptide-1 analogues: An overview - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3712370/
80GLP-1 Localisation and Proglucagon Gene Expression in ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6200298/
2TB-500 (Thymosin Beta-4) | Peptide Biologix, https://peptidebiologix.com/tb-500
12Thymosin Beta-4 vs TB-500 | What to Know in 2024, https://www.peptidesciences.com/peptide-research/thymosin-beta-4-vs-tb-500
79TMSB4X Gene: Function, Research, and Clinical Applications, https://learn.mapmygenome.in/genemap/tmsb4x